ClinicalTrials.gg
RecruitingNCT03761108LINKER-MM1Updated Oct 26, 2026

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1/2 interventional study of Linvoseltamab in Multiple Myeloma, sponsored by Regeneron Pharmaceuticals. Recruiting at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 9 months later.
Updated Oct 26, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
387
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.

Planned enrollment
4th of 16
387 · median 168
Started
2019
the only one that year
Phase 1/2
5 of 16
4 open now
Primary completion
2033-03
later than 8 of 14 live
Registered
1st of 16
by date
Lead sponsor
10 of 16
Regeneron Pharmaceuticals

Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 4th largest by planned enrollment, is the only one that started in 2019, is one of 5 in phase 1/2, reaches primary completion later than 8 of the 14 other live ones, and was the 1st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About linvoseltamab

linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing linvoseltamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by people receiving linvoseltamab
  • How linvoseltamab works in the body
  • How much linvoseltamab is present in the blood
  • How linvoseltamab may work to treat cancer
03

Conditions studied

  • Multiple Myeloma

Keywords

  • Relapsed, Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. (ECOG) performance status ≤ 1
  2. Confirmed diagnosis of active Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnostic criteria
  3. Patients must have myeloma that is response-evaluable according to the 2016 IMWG response criteria as defined in the protocol.

    • Phase 1, Part 1 (Dose Escalation): Patients with MM who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment disease or intolerance of the therapy and including either:

      a. Progression on or after at least 3 , or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory agent (IMiD), and an anti-CD38 antibody, OR b. Progression on or after an anti-CD38 antibody and have disease that is "double refractory" to a proteasome inhibitor and an IMiD, or intolerance of therapy. The anti-CD38 antibody may have been administered alone or in combination with another agent such as a proteasome inhibitor (PI). Refractory disease is defined as lack of response or relapse within 60 days of last treatment.

    • Phase 1, Part 2 (SC Administration): Patients with MM whose disease meets the following criteria:

      a. Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR b. Patients must be triple-refractory, defined as being refractory to prior treatment with at least 1 anti-CD38 antibody, a proteasome inhibitor, and an IMiD.

    • Phase 2 (Cohorts 1 and 2):

    Patients with MM whose disease meets the following criteria:

    a. Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR b. Patients must be triple- refractory, defined as being refractory* to prior treatment with at least 1 PI, 1 IMiD, and an anti-CD38 antibody.

    • Phase 2 (Cohort 3):

    Patients with MM whose disease meets the following criteria:

    1. Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR
    2. Patients must be triple- refractory, defined as being refractory* to prior treatment with at least 1 PI, 1 IMiD, and an anti-CD38 antibody.

      • Refractory disease is defined as progression during treatment or within 60 days after completion of therapy, or \<25% response to therapy.

    AND, for ALL patients, if they have relapsed after a BCMA-directed CAR-T cellular therapy then:

    • Treatment with a CAR-T must have been associated with a response of PR or better, and
    • If CAR-T cellular therapy was the most recent prior therapy, excluding , then treatment must have been a minimum of 60 days prior to treatment with linvoseltamab.

    Key Exclusion Criteria:

1. Diagnosis of plasma cell leukemia, primary systemic light-chain amyloidosis, (excluding myeloma-associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 2. Patients with known MM brain lesions or meningeal involvement 3. Cardiac \<40% by echocardiogram or multi-gated acquisition scan (MUGA) 4. Prior treatment with BCMA-directed immunotherapies, including BCMA bispecific antibodies and BiTEs. Note: BCMA antibody-drug conjugates are not excluded and BCMA-directed CAR-T treatment is not excluded in Phase 2 Cohort 3.

5. History of stem cell transplantation at any time, or autologous stem cell transplantation within 12 weeks of the start of study treatment

Note: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
387 participants (estimated)

Study arms

  • Experimental
    Linvoseltamab - Phase 1

    Phase 1 has two parts. Part 1, consists of linvoseltamab intravenous (IV) dose escalation and Part 2, consists of subcutaneous (SC) administration.

    Drug: Linvoseltamab

  • Experimental
    Linvoseltamab - Phase 2 - Cohort 1

    Low Dose of linvoseltamab IV monotherapy.

    Drug: Linvoseltamab

  • Experimental
    Linvoseltamab - Phase 2 - Cohort 2

    High Dose of linvoseltamab IV monotherapy.

    Drug: Linvoseltamab

  • Experimental
    Linvoseltamab - Phase 2 - Cohort 3

    Anti-interleukin (IL)-6 receptor (R) prophylactic therapy followed by high dose of IV linvoseltamab monotherapy.

    Drug: Linvoseltamab

Interventions

  • Administered per the protocol

    Also known as: REGN5458, Lynozyfic™

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period

    Phase 1 and Phase 2 for Japanese cohort only

    Time frame: Up to 28 days

  2. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Phase 1

    Time frame: Up to 5 years

  3. Incidence and severity of adverse events of special interest (AESI)

    Phase 1

    Time frame: Up to 5 years

  4. Assessment of the pharmacokinetics (PK) of linvoseltamab

    Phase 1 part 2

    Time frame: Up to 5 years

  5. Concentrations of linvoseltamab in serum over time

    Phase 2, for Japanese cohort only

    Time frame: Up to 5 years

  6. Objective response rate (ORR) as determined by an Independent Review Committee (IRC)

    Phase 2, cohorts 1 and 2

    Time frame: Up to 5 years

  7. Incidence and severity of cytokine release syndrome (CRS) with linvoseltamab

    Phase 2, cohort 3

    Time frame: Up to 5 years

  8. ORR of IV linvoseltamab as assessed by investigator

    Phase 2, cohort 3

    Time frame: Up to 5 years

Secondary outcomes

  1. Concentrations of linvoseltamab in the serum over time

    Phase 1 part 1 and Phase 2

    Time frame: Up to 5 years

  2. Incidence over time of anti-drug antibodies (ADAs) to linvoseltamab

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  3. Titer of anti-drug antibodies (ADAs) to linvoseltamab over time

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  4. Incidence of neutralizing antibodies (NAb) to linvoseltamab over time

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  5. Duration of response (DOR) as determined by an IRC, measured using the IMWG criteria

    Phase 2, cohorts 1 and 2

    Time frame: Up to 5 years

  6. DOR as determined by an investigator, measured using the International Myeloma Working Group (IMWG) criteria

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  7. Progression-free survival (PFS) as determined by an IRC, measured using the IMWG criteria

    Phase 2

    Time frame: Up to 5 years

  8. PFS as determined by an investigator, measured using the IMWG criteria

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  9. Rate of minimal residual disease (MRD) negative status, using the IMWG criteria

    Phase 1

    Time frame: Up to 5 years

  10. Rate of MRD negative status

    Phase 2

    Time frame: Up to 5 years

  11. Overall survival (OS)

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  12. ORR as measured as determined by blinded IRC, as measured using the IMWG criteria

    Phase 1, part 1 dose level 7 (DL7)

    Time frame: Up to 5 years

  13. ORR as determined by the investigator, measured using the IMWG criteria

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  14. Effects of linvoseltamab on health-related quality of life (HRQoL) and patient-reported symptoms and functioning per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Phase 2 The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

    Time frame: Up to 5 years

  15. Effects of linvoseltamab on HRQOL and patient-reported symptoms and functioning per Quality of Life Questionnaire-Multiple Myeloma module 20 [QLQ-MY20])

    Phase 2 The EORTC QLQ-MY20 is a self -administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems.

    Time frame: Up to 5 years

  16. Effects of linvoseltamab on HRQOL and patient-reported symptoms and functioning per EuroQoL-5 Dimension-3 Level Scale [EQ-5D-3L])

    Phase 2 The EQ-5D-3L is a self-administered generic standardized health status measure, consisting of an EQ-5D descriptive system and an EQ visual analog scale. The EQ-5D-3L descriptive system assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 3-level scale: no problems, some problems, and extreme problems. The EQ visual analog scale component is a vertical visual analog scale used by patients to rate their health.

    Time frame: Up to 5 years

  17. Change in patient-reported global health status/QoL per EORTC QLQ-C30

    Phase 2

    Time frame: Baseline up to Up to 5 years

  18. Time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30

    Phase 2

    Time frame: Up to 5 years

  19. Effects of linvoseltamab on general health status per EQ-5D-3L

    Phase 2

    Time frame: Up to 5 years

  20. Effects of linvoseltamab on patient-reported functions and symptoms per EORTC QLQ-C30

    Phase 2

    Time frame: Up to 5 years

  21. Effects of linvoseltamab on patient-reported functions and symptoms per QLQ-MY20

    Phase 2

    Time frame: Up to 5 years

  22. Incidence and severity of TEAEs with linvoseltamab

    Phase 2

    Time frame: Up to 5 years

  23. Incidence and severity of AESIs with linvoseltamab

    Phase 2

    Time frame: Up to 5 years

07

Study locations

25 of 40 sites recruiting
08

References and documents

Publications

  • Hoffman JE, Bumma N, Richter J, Dhodapkar MV, Lee HC, Suvannasankha A, Zonder JA, Maly JJ, Shah MR, Baz R, Inocencio TJ, DeVeaux M, Ivanescu C, Rodriguez Lorenc K, Kroog GS, Knorr K, Chi L, Harnett J, Ma Q, Jagannath S. Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1. Blood Neoplasia. 2026 Mar 27;3(3):100225. doi: 10.1016/j.bneo.2026.100225. eCollection 2026 Aug. PubMed 42564571 ↗
  • Lowy JA, Rogers MF, Avigan ZM, Flores MS, Samuel M, Rattu MA, Richter J. Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen. Expert Rev Hematol. 2026 Apr;19(4):361-372. doi: 10.1080/17474086.2026.2634283. Epub 2026 Mar 4. PubMed 41708325 ↗
  • Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martinez-Lopez J, DeVeaux M, Roccia T, Chokshi D, Seraphin M, Knorr K, Boyapati A, Hazra A, Rodriguez Lorenc K, Kroog GS, Bumma N, Richter J. Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Clin Lymphoma Myeloma Leuk. 2026 Feb;26(2):e201-e212.e8. doi: 10.1016/j.clml.2025.11.004. Epub 2025 Nov 12. PubMed 41387038 ↗
  • Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martinez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024 Aug 1;42(22):2702-2712. doi: 10.1200/JCO.24.01008. Epub 2024 Jun 16. PubMed 38879802 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in a manuscript. Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Mar 2033, 170 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 170 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Dec 3, 2018
StartActual
Jan 23, 2019
Primary completionEst.
Mar 30, 2033
CompletionEst.
Jun 16, 2033
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Cliniques Universitaires Saint-Luc is now Completed
Oct 26, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 42564571 ↗
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 42564571 ↗
    Cliniques Universitaires Saint-Luc is now Completed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03761108
Responsible party
Sponsor
First posted
Dec 3, 2018
Start date
Jan 23, 2019
Primary completion
Mar 30, 2033 (estimated)
Completion
Jun 16, 2033 (estimated)
Last update
Oct 26, 2026

Study contacts

Clinical Trial Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion